Alessandro Rambaldi

Nov 11, 2024 | nature.com | Joanna Drozd-Sokolowska |František Folber |Grzegorz W. Basak |Jane F. Apperley |Alessandro Rambaldi |Marek Trneny | +6 more

AbstractAutologous hematopoietic cell transplants (auto-HCTs) remain the standard of care for transplant-eligible MM patients. The general practice has been to undergo upfront apheresis following induction to collect sufficient number of CD34+ cells to facilitate two auto-HCTs. However, 5–30% of MM patients do not initially mobilise a sufficient number of hematopoietic stem cells and are classified as poor mobilizers (PM).

Nov 5, 2024 | nature.com | Tiziano Barbui |Alessandra Carobbio |Alessandro Vannucchi |Paola Guglielmelli |Alessandro Rambaldi |Naseema Gangat

AbstractWe analyzed the neutrophil-to-lymphocyte ratio (NLR) in 1508 patients with PV and found that those with an NLR ≥ 5 were generally older, had a longer disease history, and had higher cardiovascular risk factors, more arterial thrombosis, and more aggressive blood counts, indicating a more proliferative disease.

Oct 24, 2024 | nature.com | Tiziano Barbui |Alessandra Carobbio |Valerio De Stefano |Alessandro Rambaldi |Ayalew Tefferi

AbstractThis viewpoint summarizes findings from analyses of large personal patient databases of myeloproliferative neoplasms (MPNs) to assess the impact of thrombosis on mortality, disease progression, and second cancers (SC). Despite advances, the current incidence of arterial and venous thrombosis remains a challenge.

Jul 28, 2023 | nature.com | Alessandra Carobbio |Elisa Rumi |Valerio De Stefano |Alessandro Rambaldi |Francesco Passamonti |Naseema Gangat | +1 more

Dear EditorAmple evidence has been provided that accurate discrimination between essential thrombocythemia (ET) and early prefibrotic primary myelofibrosis (pre-PMF) has an impact not only on presenting laboratory data but also on complications, like thrombosis, progression to overt myelofibrosis (MF), transformation to blast phase (BP), and overall survival [1,2,3,4,5,6,7,8].